bioRxiv Science⌕ Search

Biology subjects

Olsen, C.

Publications and source records attributed to Olsen, C..

10 recordsLinked to original sources

Constrained protein Large Language Model illustrated in protein stability, function and epistasis

Our understanding of protein function and evolution is largely based on the relationship between amino acid sequence and overall fold, now effectively captured by computational models. Yet predicting how mutations--shaped by epistasis--alter protein behavior, especially in dynamic or structurally ambiguous regions, remains difficult. Here we present D2D, which combines a self-supervised protein language model with protein-specific evolutionary information to predict mutational effects using little to no task-specific labeled data. D2D captures long-range epistatic interactions, accurately predicts single and higher-order mutation effects on protein thermostability and binding, without being trained on the task. When fine-tuned, D2D outperforms state-of-the-art methods on latent driver cancer mutations and co-occurring proliferation-enhancing mutations across independent experimental studies. Unlike most existing approaches, D2D avoids biases linked to solvent accessibility or to multiple sequence alignment depth and quality, making it particularly effective for disordered or surface binding regions where structure-based predictors typically falter. Overall, D2D provides a general framework for modeling mutational effects in proteins with limited experimental or structural information.

bioinformatics↗

De novo cancer mutations frequently associate with recurrent chromosomal abnormalities during long-term human pluripotent stem cell culture

Human pluripotent stem cells (hPSC) are pivotal in regenerative medicine, yet their in vitro expansion often leads to genetic abnormalities, raising concerns about their safety in clinical applications. This study analyzed ten human embryonic stem cell lines across multiple passages to elucidate the dynamics of chromosomal abnormalities and single nucleotide variants (SNVs) in 380 cancer-related genes. Prolonged in vitro culture resulted in 80% of the lines acquiring gains of chromosomes 20q or 1q, both known for conferring in vitro growth advantage. 70% of lines also acquired other copy number variants (CNVs) outside the recurrent set. Additionally, we detected 122 SNVs in 88 genes, with all lines acquiring at least one de novo SNV during culture. Our findings show higher loads of both CNVs and SNVs at later passages which are due to the cumulative acquisition of mutations over a longer time in culture and not to an increased rate of mutagenesis over time. Importantly, we observed that SNVs and rare CNVs follow the acquisition of chromosomal gains in 1q and 20q, while most of the low-passage and genetically balanced samples were devoid cancer-associated mutations. This suggests that the recurrent chromosomal abnormalities are the potential drivers for the acquisition of other mutations.

cell biology↗

Combining evolution and protein language modelsfor an interpretable cancer driver mutationprediction with D2Deep

The mutations driving cancer are being increasingly exposed through tumor-specific genomic data. However, differentiating between cancer-causing driver mutations and random passenger mutations remains challenging. State-of-the-art homology-based predictors contain built-in biases and are often ill-suited to the intricacies of cancer biology. Protein Language Models have successfully addressed various biological problems but have not yet been tested on the challenging task of cancer driver mutation prediction at large scale. Additionally, they often fail to offer result interpretation, hindering their effective use in clinical settings. The AI-based D2Deep method we introduce here addresses these challenges by combining two powerful elements: i) a non-specialized protein language model that captures the makeup of all protein sequences and ii) protein-specific evolutionary information that encompasses functional requirements for a particular protein. D2Deep relies exclusively on sequence information, outperforms state-of-the-art predictors and captures intricate epistatic changes throughout the protein caused by mutations. These epistatic changes correlate with known mutations in the clinical setting and can be used for the interpretation of results. The model is trained on a balanced, somatic training set and so effectively mitigates biases related to hotspot mutations compared to state-of-the-art techniques. The versatility of D2Deep is illustrated by its performance on non-cancer mutation prediction, where most variants still lack known consequences. D2Deep predictions and confidence scores are available via https://tumorscope.be/d2deep to help with clinical interpretation and mutation prioritization.

bioinformatics↗

Simultaneous LC-MS determination of glucose regulatory peptides secreted by stem cell-derived islet organoids

For studying stem cell-derived islet organoids (SC-islets) in an organ-on-chip platform, we have developed a reversed phase liquid chromatography tandem mass spectrometry (RPLC-MS/MS) method allowing for simultaneous determination of insulin, somatostatin-14, and glucagon, with improved matrix robustness compared to earlier methodology. Combining phenyl/hexyl-C18 separations using 2.1 mm inner diameter LC columns and triple quadrupole mass spectrometry, identification and quantification were secured with negligible variance in retention time and quantifier/qualifier ratios, negligible levels of carry-over (< 2%), and sufficient precision ({+/-} 10% RSD) and accuracy ({+/-} 15% relative error) with and without use of internal standard. The here developed RPLC-MS/MS method showed that the SC-islets have an insulin response dependent on glucose concentration, and the SC-islets produce and release somatostatin-14 and glucagon. The RPLC-MS/MS method for these peptide hormones was compatible with an unfiltered off-line sample collection from SC-islets cultivated on a pump-less, recirculating organ-on-chip (rOoC) platform. The SC-islets background secretion of insulin was not significantly different on the rOoC device compared to a standard cell culture well-plate. Taken together, RPLC-MS/MS is well suited for multi-hormone measurements of SC-islets on an organ-on-chip platform.

biochemistry↗

An Automatized Workflow to Study Mechanistic Indicators for Driver Gene Prediction with Moonlight

Prediction of tumor suppressors and oncogenes, also called driver genes, is an essential step in understanding cancer development and discovering potential novel treatments. We recently proposed Moonlight as a bioinformatics framework to predict driver genes and analyze them in a system-biology-oriented manner based on -omics integration. Moonlight uses gene expression as a primary data source and combines it with patterns related to cancer hallmarks and regulatory networks to identify oncogenic mediators. Once the oncogenic mediators are identified, it is important to include extra levels of evidence, called mechanistic indicators, to identify driver genes and to link the observed changes in gene expression to the underlying alteration that promotes them. Such a mechanistic indicator could be for example a mutation in the regulatory regions for the candidate gene or mutations in the regulator itself. In this work, we developed new functionalities and release Moonlight2, to provide the user with the mutation-based mechanistic indicator to streamline the analyses of this second layer of evidence. The function analyzes mutation information in a cancer cohort to classify them into driver and passenger mutations. Moreover, the function estimates the potential effect of a mutation on the transcriptional, translational, or protein structure/function level. Those oncogenic mediators with at least one driver mutation are retained as the final set of driver genes. We applied Moonlight2 and the newly developed function to a case study on Basal-like breast cancer subtype using data from The Cancer Genome Atlas. We found six oncogenes (SF3B4, EBNA1BP2, KRTCAP2, ZBTB8OS, RUNX2, and POLR2J) and ten tumor suppressor genes (KIF26B, NR5A2, ARHGAP25, EMCN, ARL15, PCOLCE, TPK1, TEK, KIR2DL4, and GMFG) containing a driver mutation in their promoter region, possibly explaining their deregulation. The Moonlight2R source code is available at https://github.com/ELELAB/Moonlight2R.

bioinformatics↗

Determination of insulin secretion from stem cell-derived islets with liquid chromatography-tandem mass spectrometry

Organoids are laboratory-grown 3D organ models, mimicking human organs for e.g. drug development and personalized therapy. Islet organoids (typically 100-200 m), which can be grown from the patients own cells, are emerging as prototypes for transplantation-based therapy of diabetes. Selective methods for quantifying insulin production from islet organoids are needed, but sensitivity and carry-over have been major bottlenecks in previous efforts. We have developed a reverse phase liquid chromatography-tandem mass spectrometry (RPLC-MS/MS) method for studying the insulin secretion of islet organoids. In contrast to our previous attempts using nano-scale LC columns, conventional 2.1 mm inner diameter LC column (combined with triple quadrupole mass spectrometry) was well suited for sensitive and selective measurements of insulin secreted from islet organoids with low microliter-scale samples. Insulin is highly prone to carry-over, so standard tubings and injector parts were replaced with shielded fused silica nanoViper connectors. As samples were expected to be very limited, an extended Box-Behnken experimental design for the MS settings was conducted to maximize performance. The finale method has excellent sensitivity, accuracy and precision (limit of detection: [&le;] 0.2 pg/L, relative error: [&le;] {+/-}10%, relative standard deviation: < 10%), and was well suited for measuring 20 L amounts of Krebs buffer containing insulin secreted from islet organoids.

bioengineering↗

Host Genetic Background and Gut Microbiota Contribute to Differential Metabolic Responses to High Fructose Consumption in Mice

BackgroundIt is unclear how high fructose consumption induces disparate metabolic responses in genetically diverse mouse strains. ObjectiveWe aim to investigate whether the gut microbiota contributes to differential metabolic responses to fructose. MethodsEight-week-old male C57BL/6J (B6), DBA/2J (DBA), and FVB/NJ (FVB) mice were given 8% fructose solution or regular water (control) for 12 weeks. The gut microbiota composition in cecum and feces was analyzed using 16S rDNA sequencing, and PERMANOVA was used to compare community across mouse strains, treatments, and time points. Microbiota abundance was correlated with metabolic phenotypes and host gene expression in hypothalamus, liver and adipose tissues using Biweight midcorrelation. To test the causal role of the gut microbiota in determining fructose response, we conducted fecal transplants from B6 to DBA mice and vice versa for 4 weeks, as well as gavaged antibiotic-treated DBA mice with Akkermansia for 9 weeks, accompanied with or without fructose treatment. ResultsCompared to B6 and FVB, DBA mice had significantly higher Firmicutes/Bacteroidetes ratio and lower baseline levels of Akkermansia and S24-7 (P < 0.05), accompanied by metabolic dysregulation after fructose consumption. Fructose altered specific microbial taxa in individual mouse strains, such as a 7.27-fold increase in Akkermansia in B6 and 0.374-fold change in Rikenellaceae in DBA (FDR < 5%), which demonstrated strain-specific correlations with host metabolic and transcriptomic phenotypes. Fecal transplant experiments indicated that B6 microbes conferred resistance to fructose-induced weight gain in DBA mice (F = 43.1, P < 0.001), and Akkermansia colonization abrogated the fructose-induced weight gain (F = 17.8, P <0.001) and glycemic dysfunctions (F = 11.8, P = 0.004) in DBA mice. ConclusionsOur findings support that differential microbiota composition between mouse strains is partially responsible for host metabolic sensitivity to fructose, and that Akkermansia is a key bacterium that confers resistance to fructose-induced metabolic dysregulation.

systems biology↗

Analyses of cancer data in the Genomic Data Commons Data Portal with new functionalities in the TCGAbiolinks R/Bioconductor package

The advent of Next Generation Sequencing (NGS) technologies has opened new perspectives in deciphering the genetic mechanisms underlying complex diseases. Nowadays, the amount of genomic data is massive and substantial efforts and new tools are required to unveil the information hidden in the data.\n\nThe Genomic Data Commons (GDC) Data Portal is a large data collection platform that includes different genomic studies included the ones from The Cancer Genome Atlas (TCGA) and the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiatives, accounting for more than 40 tumor types originating from nearly 30000 patients. Such platforms, although very attractive, must make sure the stored data are easily accessible and adequately harmonized. Moreover, they have the primary focus on the data storage in a unique place, and they do not provide a comprehensive toolkit for analyses and interpretation of the data. To fulfill this urgent need, comprehensive but easily accessible computational methods for integrative analyses of genomic data without renouncing a robust statistical and theoretical framework are needed. In this context, the R/Bioconductor package TCGAbiolinks was developed, offering a variety of bioinformatics functionalities. Here we introduce new features and enhancements of TCGAbiolinks in terms of i) more accurate and flexible pipelines for differential expression analyses, ii) different methods for tumor purity estimation and filtering, iii) integration of normal samples from the Genotype-Tissue-Expression (GTEx) platform iv) support for other genomics datasets, here exemplified by the TARGET data.\n\nEvidence has shown that accounting for tumor purity is essential in the study of tumorigenesis, as these factors promote confounding behavior regarding differential expression analysis. Henceforth, we implemented these filtering procedures in TCGAbiolinks. Moreover, a limitation of some of the TCGA datasets is the unavailability or paucity of corresponding normal samples. We thus integrated into TCGAbiolinks the possibility to use normal samples from the Genotype-Tissue Expression (GTEx) project, which is another large-scale repository cataloging gene expression from healthy individuals. The new functionalities are available in the TCGABiolinks v 2.8 and higher released in Bioconductor version 3.7.

bioinformatics↗

Moonlight: a tool for biological interpretation and driver genes discovery

Cancer is a complex and heterogeneous disease. It is crucial to identify the key driver genes and their role in cancer mechanisms with attention to different cancer stages, types or subtypes. Cancer driver genes are elusive and their discovery is complicated by the fact that the same gene can play a diverse role in different contexts. Key biological processes, such as cell proliferation and cell death, have been linked to cancer progression. Thus, in principle, they can be exploited to classify the cancer genes and unveil their role. Here, we present a new method, Moonlight, that exploit expression data to classify cancer genes. Moonlight relies on the integration of functional enrichment analysis, gene regulatory networks and upstream regulator analysis from expression data to score the importance of biological cancer-related processes taking into account either the inter- or intra-tumor heterogeneity. We then employed these scores to predict if each gene acts as a tumor suppressor gene (TSG) or as an oncogene (OCG). Our methodology also allow to predict genes with dual role, i.e. the moonlight genes (TSG in one cancer type or stage and OCG in another), as well as to elucidate the underlying biological processes. Availability: https://bioconductor.org/packages/MoonlightR & https://github.com/ibsquare/MoonlightR/

bioinformatics↗

TCGAbiolinksGUI: A graphical user interface to analyze cancer molecular and clinical data

BackgroundThe GDC (Genomic Data Commons) data portal provides users with data from cancer genomics studies. Recently, we developed the R/Bioconductor TCGAbiolinks package, which allows users to search, download and prepare cancer genomics data for integrative data analysis. The use of this package requires users to have advanced knowledge of R thus limiting the number of users.\n\nResultsTo overcome this obstacle and improve the accessibility of the package by a wider range of users, we developed TCGAbiolinksGUI that uses shiny graphical user interface (GUI) available through the R/Bioconductor package.\n\nConclusionThe TCGAbiolinksGUI package is freely available within the Bioconductor project at http://bioconductor.org/packages/TCGAbiolinksGUI/. Links to the GitHub repository, a demo version of the tool, a docker image and PDF/video tutorials are available at http://bit.do/TCGAbiolinksDocs.

bioinformatics↗